## Nadja Maric

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5770669/publications.pdf

Version: 2024-02-01

ors
,

#	Article	IF	CITATIONS
1	EPA guidance on the early intervention in clinical high risk states of psychoses. European Psychiatry, 2015, 30, 388-404.	0.1	390
2	EPA guidance on the early detection of clinical high risk states of psychoses. European Psychiatry, 2015, 30, 405-416.	0.1	318
3	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	2.3	229
4	Hypopituitarism as a consequence of traumatic brain injury (TBI) and its possible relation with cognitive disabilities and mental distress. Journal of Endocrinological Investigation, 2004, 27, 1048-1054.	1.8	168
5	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry, 2019, 18, 173-182.	4.8	127
6	Therapeutic Strategies for Treatment of Inflammation-related Depression. Current Neuropharmacology, 2018, 16, 176-209.	1.4	107
7	Sex differences in symptoms of psychosis in a non-selected, general population sample. Schizophrenia Research, 2003, 63, 89-95.	1.1	103
8	Pathways to psychiatric care in Eastern Europe. British Journal of Psychiatry, 2005, 186, 529-535.	1.7	84
9	Why schizophrenia genetics needs epigenetics: a review. Psychiatria Danubina, 2012, 24, 2-18.	0.2	82
10	Psychiatric and neuropsychological changes in growth hormone-deficient patients after traumatic brain injury in response to growth hormone therapy. Journal of Endocrinological Investigation, 2010, 33, 770-775.	1.8	70
11	Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine. Autophagy, 2014, 10, 2362-2378.	4.3	66
12	Worldwide implementation of clinical services for the prevention of psychosis: The IEPA early intervention in mental health survey. Microbial Biotechnology, 2020, 14, 741-750.	0.9	58
13	Changes in Neuroendocrine and Metabolic Hormones Induced by Atypical Antipsychotics in Normal-Weight Patients with Schizophrenia. Neuroendocrinology, 2007, 85, 249-256.	1.2	50
14	Improving Current Treatments for Schizophrenia. Drug Development Research, 2016, 77, 357-367.	1.4	46
15	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. Schizophrenia Bulletin, 2019, 45, 960-965.	2.3	46
16	Pharmacological modulation of HPA axis in depression - new avenues for potential therapeutic benefits. Psychiatria Danubina, 2013, 25, 299-305.	0.2	40
17	Is our concept of schizophrenia influenced by Berkson's bias?. Social Psychiatry and Psychiatric Epidemiology, 2004, 39, 600-605.	1.6	38
18	Prenatal stress during the 1999 bombing associated with lower birth weightâ€"a study of 3,815 births from Belgrade. Archives of Women's Mental Health, 2010, 13, 83-89.	1.2	38

#	Article	IF	CITATIONS
19	Bone Remodeling, Bone Mass and Weight Gain in Patients with Stabilized Schizophrenia in Real-Life Conditions Treated with Long-Acting Injectable Risperidone. Neuroendocrinology, 2011, 94, 246-254.	1.2	38
20	Mechanisms and therapeutic significance of autophagy modulation by antipsychotic drugs. Cell Stress, 2018, 2, 282-291.	1.4	38
21	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. Epidemiology and Psychiatric Sciences, 2020, 29, e182.	1.8	36
22	Gait characteristics in patients with major depression performing cognitive and motor tasks while walking. Psychiatry Research, 2014, 217, 39-46.	1.7	32
23	Stigmatization of †psychiatric label' by medical and non-medical students. International Journal of Social Psychiatry, 2012, 58, 455-462.	1.6	30
24	Do depressive symptoms on hospital admission impact early functional outcome in elderly patients with hip fracture?. Psychogeriatrics, 2014, 14, 118-123.	0.6	29
25	Lymphocyte Levels of Redox-Sensitive Transcription Factors and Antioxidative Enzymes as Indicators of Pro-Oxidative State in Depressive Patients. Neuropsychobiology, 2014, 70, 1-9.	0.9	29
26	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study. Psychological Medicine, 2020, 50, 1884-1897.	2.7	28
27	Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis. Schizophrenia Research, 2005, 73, 351-355.	1.1	27
28	Phosphorylation of leukocyte glucocorticoid receptor in patients with current episode of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 40, 281-285.	2.5	25
29	The acute and medium-term effects of treatment with electroconvulsive therapy on memory in patients with major depressive disorder. Psychological Medicine, 2016, 46, 797-806.	2.7	23
30	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	4.1	23
31	Accumulation of Cytoplasmic Glucocorticoid Receptor Is Related to Elevation of FKBP5 in Lymphocytes of Depressed Patients. Journal of Molecular Neuroscience, 2015, 55, 951-958.	1.1	21
32	The emerging role of the FKBP5 gene polymorphisms in vulnerability–stress model of schizophrenia: further evidence from a Serbian population. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 527-539.	1.8	20
33	Prescribing practices in Southeastern Europe – focus on benzodiazepine prescription at discharge from nine university psychiatric hospitals. Psychiatry Research, 2017, 258, 59-65.	1.7	19
34	Prescribing practices in psychiatric hospitals in Eastern Europe. European Psychiatry, 2011, 26, 414-418.	0.1	18
35	Familial covariation of facial emotion recognition and IQ in schizophrenia. Psychiatry Research, 2016, 246, 52-57.	1.7	18
36	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Psychiatry, 2021, 64, e25.	0.1	18

#	Article	IF	Citations
37	Neuroticism and facial emotion recognition in healthy adults. Microbial Biotechnology, 2016, 10, 160-164.	0.9	17
38	Implementing a psychosocial intervention DIALOG+ for patients with psychotic disorders in low and middle income countries in South Eastern Europe: protocol for a hybrid effectiveness-implementation cluster randomized clinical trial (IMPULSE). Global Psychiatry, 2020, 3, 83-96.	2.0	17
39	A preliminary evaluation of leukocyte phospho-glucocorticoid receptor as a potential biomarker of depressogenic vulnerability in healthy adults. Psychiatry Research, 2013, 209, 658-664.	1.7	16
40	Retinal structural abnormalities in young adults with psychosis spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 98, 109825.	2.5	16
41	Relation between cerebrospinal fluid, gray matter and white matter changes in families with schizophrenia. Journal of Psychiatric Research, 2006, 40, 646-655.	1.5	15
42	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine, 2022, 52, 1910-1922.	2.7	14
43	Metabolic issues in psychotic disorders with the focus on first-episode patients: a review. Psychiatria Danubina, 2013, 25, 410-5.	0.2	14
44	Survey of the European Psychiatric Association on the European status and perspectives in early detection and intervention in atâ€risk mental state and firstâ€episode psychosis. Microbial Biotechnology, 2019, 13, 853-858.	0.9	11
45	On the origin of schizophrenia: Testing evolutionary theories in the postâ€genomic era. Psychiatry and Clinical Neurosciences, 2019, 73, 723-730.	1.0	11
46	Sex differences in facial emotion recognition in health and psychotic disorders. Cognitive Neuropsychiatry, 2019, 24, 108-122.	0.7	11
47	Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression. Medical Hypotheses, 2015, 85, 291-294.	0.8	10
48	European status and perspectives on early detection and intervention in at-risk mental state and first episode psychosis: Viewpoint from the EPA section for prevention of mental disorders. European Psychiatry, 2017, 46, 48-50.	0.1	10
49	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. Psychological Medicine, 2022, 52, 1777-1783.	2.7	10
50	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110440.	2.5	10
51	Covid-19-related stressors, mental disorders, depressive and anxiety symptoms: a cross-sectional, nationally-representative, face-to-face survey in Serbia. Epidemiology and Psychiatric Sciences, 2022, 31,	1.8	10
52	Postgraduate training for young psychiatristsâ€"experience of the Berlin Summer School. European Psychiatry, 2006, 21, 509-515.	0.1	9
53	The role of glucocorticoid receptor phosphorylation in the model of negative affective states. World Journal of Biological Psychiatry, 2015, 16, 301-311.	1.3	8
54	How medical students in their pre-clinical year perceive psychiatry as a career: the study from Belgrade. Psychiatria Danubina, 2009, 21, 206-12.	0.2	8

#	Article	IF	CITATIONS
55	Electroconvulsive therapy practice in Serbia today. Psychiatria Danubina, 2014, 26, 66-9.	0.2	8
56	Factors influencing the choice of antidepressants: A study of antidepressant prescribing practice at University psychiatric clinic in Belgrade. Vojnosanitetski Pregled, 2012, 69, 308-313.	0.1	7
57	Chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 46, 58-63.	2.5	7
58	»Treatment Resistance« Enigma Resolved by Pharmacogenomics â^ A Case Study of Clozapine Therapy in Schizophrenia / Enigma »Terapo-Rezistence« RazreÅ¡ena Uz Pomoć Farmakogenomike - Prikaz Slućaja Terapije Klozapinom U Shizofreniji. Journal of Medical Biochemistry, 2015, 34, 223-227.	0.7	7
59	Structural imaging of the retina in psychosis spectrum disorders. Current Opinion in Psychiatry, 2020, Publish Ahead of Print, 476-483.	3.1	7
60	The FKBP5 genotype and childhood trauma effects on FKBP5 DNA methylation in patients with psychosis, their unaffected siblings, and healthy controls. Psychoneuroendocrinology, 2021, 128, 105205.	1.3	7
61	Use or underuse of therapeutic guidelines in psychiatry?. Psychiatria Danubina, 2009, 21, 224-9.	0.2	7
62	Effective assessment of psychotropic medication side effects using PsyLOG mobile application. Schizophrenia Research, 2018, 192, 211-212.	1.1	6
63	Long-Term Benzodiazepine Prescription During Maintenance Therapy of Individuals With Psychosis Spectrum Disorders—Associations With Cognition and Global Functioning. Clinical Neuropharmacology, 2021, 44, 89-93.	0.2	6
64	Sex differences in macular thickness of the retina in patients with psychosis spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110280.	2.5	6
65	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. Frontiers in Psychiatry, 2019, 10, 676.	1.3	5
66	Implementation of early detection and intervention services for psychosis in Central and Eastern Europe: Current status. Microbial Biotechnology, 2019, 13, 1283-1288.	0.9	5
67	Efficacy, tolerability and safety of tianeptine in special populations of depressive patients. Psychiatria Danubina, 2009, 21, 194-8.	0.2	5
68	Change of students interest in psychiatry over the years at school of medicine, University of Belgrade, Serbia. Israel Journal of Psychiatry, 2011, 48, 42-8.	0.2	5
69	Non-pharmacological interventions for schizophrenia—analysis of treatment guidelines and implementation in 12 Southeast European countries. NPJ Schizophrenia, 2022, 8, 10.	2.0	5
70	Glucocorticoid receptor alpha translational isoforms as mediators of early adversities and negative emotional states. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 90, 288-299.	2.5	4
71	Mental health in the second year of the COVID-19 pandemic: protocol for a nationally representative multilevel survey in Serbia. BMJ Open, 2021, 11, e053835.	0.8	4
72	Mental health and COVID-19 pandemic: The literature review. Medicinski Podmladak, 2021, 72, 78-86.	0.2	4

#	Article	lF	CITATIONS
73	Changes in antipsychotic prescription practice at University Hospital in Belgrade, Serbia: 2009 vs. 2004. Acta Psychiatrica Scandinavica, 2011, 123, 495-495.	2.2	3
74	Population-based differences in immune system response contribute to an increased risk of schizophrenia in African migrants?. Reviews in the Neurosciences, 2018, 29, 347-353.	1.4	3
75	Non-pharmacological treatments for schizophrenia in Southeast Europe: An expert survey. International Journal of Social Psychiatry, 2021, , 002076402110230.	1.6	3
76	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 201-219.	1.0	3
77	Factors influencing the choice of antidepressants: a study of antidepressant prescribing practice at University Psychiatric Clinic in Belgrade. Vojnosanitetski Pregled, 2012, 69, 308-13.	0.1	3
78	Probable depression and anxiety in seven European countries during the COVID-19: Probable overestimation of the problem due to sampling method. Journal of Affective Disorders, 2022, 311, 554-555.	2.0	3
79	Psychological morbidity during pregnancy and low birth weight. British Journal of Psychiatry, 2006, 188, 586-586.	1.7	2
80	Executive function in treatment-resistant depression before and after electroconvulsive therapy. World Journal of Biological Psychiatry, 2017, 18, 624-632.	1.3	2
81	Openness to experience shortens duration of untreated psychosis in Serbian clinical population. Microbial Biotechnology, 2018, 12, 91-95.	0.9	2
82	Determinants of quality of life among individuals seeking mental health care after termination of state of emergency due to the coronavirus disease 2019 pandemic. Medicine (United States), 2021, 100, e26854.	0.4	2
83	The research team of the CoV2Soul.RS project, reports the preliminary results on depressiveness in Serbia, on the occasion of the world mental health day. Srpski Medicinski Äasopis Lekarske Komore, 2021, 2, 337-341.	0.1	2
84	Parricide in the region of Belgrade: Descriptive analysis. European Psychiatry, 2008, 23, S336.	0.1	1
85	Frequency and correlates of depression at the primary health care level in Belgrade. Srpski Arhiv Za Celokupno Lekarstvo, 2020, 148, 185-190.	0.1	1
86	The classification of psychotic disorders: Trending topics. Engrami, 2019, 41, 85-100.	0.1	1
87	Community attitudes towards the mentally ill in Serbia. Engrami, 2019, 41, 50-67.	0.1	1
88	Risperidone liquid in psychotic disorders-efficacy and attitudes. Psychiatria Danubina, 2005, 17, 191-6.	0.2	1
89	Depression following Traumatic Brain Injury Associated with Isolated Growth Hormone Deficiency: Two Case Reports. Hormone Research in Paediatrics, 2007, 67, 177-179.	0.8	0
90	P.4.a.003 Sex differences in susceptibility to adverse effects of prenatal stress on birth weight: study of 2516 Belgrade newborns. European Neuropsychopharmacology, 2009, 19, S587.	0.3	0

#	Article	IF	CITATIONS
91	P.2.b.003 Assessment of impaired glucocorticoid signaling in negative affective states via FKBP51 and glucocorticoid receptor phosphorylation. European Neuropsychopharmacology, 2014, 24, S379.	0.3	O
92	SU94. Allele-Specific and Trauma-Related Epigenetic Changes in the FKBP5 Gene: Differences Between Psychotic Patients and Healthy Controls. Schizophrenia Bulletin, 2017, 43, S195-S195.	2.3	0
93	Facial emotion recognition in schizophrenia spectrum disorders – how polypharmacy impacts processing speed. European Neuropsychopharmacology, 2019, 29, S123.	0.3	0
94	S211. LONG-TERM BENZODIAZEPINE USE DURING MAINTENANCE THERAPY OF PSYCHOSIS - ASSOCIATION WITH SYMPTOMS, COGNITION AND FUNCTIONALITY. Schizophrenia Bulletin, 2020, 46, S119-S119.	2.3	0
95	Recognition and treatment of hyponatremia in psychiatric practice: Analysis of the frequency and report of case series. Engrami, 2019, 41, 112-125.	0.1	O
96	Schizotypy: Current concepts and future research implications. Medicinski Podmladak, 2019, 70, 27-33.	0.2	0
97	Duration of psychiatric appointments for patients with Psychosis spectrum disorders in Serbia: Is it significantly prolonged by DIALOG+ psychosocial intervention?. Psihijatrija Danas, 2020, 52, 13-24.	0.1	O
98	Risperidon vs. Other antipsychotics in schizophrenia: the assessment of patients' attitudes. Psychiatria Danubina, 2004, 16, 127-31.	0.2	0
99	Maintenance Therapy of Psychosis Spectrum Disorders in a Real-World Setting: Antipsychotics Prescription Patterns and Long-Term Benzodiazepine Use. Frontiers in Psychiatry, 2022, 13, 796719.	1.3	0
100	Recovering quality of life in outpatients with psychosis spectrum disorders and its association with the symptom domains., 2022, 55, 43-49.		O